Natoli Clara, Brocco Davide, Sperduti Isabella, Nuzzo Antonio, Tinari Nicola, De Tursi Michele, Grassadonia Antonino, Mazzilli Lorenzo, Iacobelli Stefano, Gamucci Teresa, Vici Patrizia
Department of Experimental and Clinical Sciences, University "G. d'Annunzio", Chieti, Italy.
Unit of Biostatistics, Regina Elena National Cancer Institute, Rome, Italy.
PLoS One. 2014 Apr 8;9(4):e94063. doi: 10.1371/journal.pone.0094063. eCollection 2014.
Breast cancer follow-up procedures after primary treatment are still a controversial issue. Aim of this study was to investigate, through a web-based survey, surveillance methodologies selected by Italian oncologists in everyday clinical practice.
Referents of Italian medical oncology units were invited to participate to the study via e-mail through the SurveyMonkey website. Participants were asked how, in their institution, exams of disease staging and follow-up are planned in asymptomatic women and if surveillance continues beyond the 5th year.
Between February and May 2013, 125 out of 233 (53.6%) invited referents of Italian medical oncology units agreed to participate in the survey. Ninety-seven (77.6%) referents state that modalities of breast cancer follow-up are planned according to the risk of disease progression at diagnosis and only 12 (9.6%) oncology units apply the minimal follow-up procedures according to international guidelines. Minimal follow-up is never applied in high risk asymptomatic women. Ninety-eight (78.4%) oncology units continue follow-up in all patients beyond 5 years.
Our survey shows that 90.4% of participating Italian oncology units declare they do not apply the minimal breast cancer follow-up procedures after primary treatment in asymptomatic women, as suggested by national and international guidelines. Interestingly, about 80.0% of interviewed referents performs the so called "tailored follow-up", high intensity for high risk, low intensity for low risk patients. There is an urgent need of randomized clinical trials able to determine the effectiveness of risk-based follow-up modalities, their ideal frequency and persistence in time.
乳腺癌初始治疗后的随访程序仍是一个有争议的问题。本研究旨在通过一项基于网络的调查,探究意大利肿瘤学家在日常临床实践中选择的监测方法。
通过SurveyMonkey网站以电子邮件邀请意大利医学肿瘤学单位的负责人参与研究。参与者被问及在其机构中,针对无症状女性的疾病分期检查和随访是如何规划的,以及随访是否会持续超过5年。
在2013年2月至5月期间,233名受邀的意大利医学肿瘤学单位负责人中有125名(53.6%)同意参与调查。97名(77.6%)负责人表示,乳腺癌随访方式是根据诊断时疾病进展风险来规划的,只有12个(9.6%)肿瘤学单位按照国际指南采用最低限度的随访程序。对于高风险无症状女性,从不采用最低限度的随访。98个(78.4%)肿瘤学单位在所有患者5年后继续进行随访。
我们的调查显示,90.4%参与调查的意大利肿瘤学单位宣称,他们在无症状女性初始治疗后未按照国家和国际指南建议采用最低限度的乳腺癌随访程序。有趣的是,约80.0%接受访谈的负责人采用了所谓的“个性化随访”,即对高风险患者采用高强度,对低风险患者采用低强度。迫切需要进行随机临床试验,以确定基于风险的随访方式的有效性、理想的随访频率以及随访时间的持续性。